Xcell Biosciences Enhances Production Capabilities with AmplifyBio
Xcell Biosciences Boosts Collaboration with AmplifyBio
Xcell Biosciences Inc. (Xcellbio), an innovator in instrumentation for cell and gene therapy applications, is thrilled to announce an expansion of its collaboration with AmplifyBio, a dynamic player in the contract development and manufacturing landscape. This enhancement involves the installation of the new AVATAR™ Foundry system as part of Xcellbio’s beta access initiative. This cutting-edge instrument will allow AmplifyBio to evolve its operations from small-scale processes executed on the earlier AVATAR™ Odyssey platform to automated manufacturing workflows that meet clinical specifications.
Advancing T-Cell Receptor Therapies
The partnership between Xcellbio and AmplifyBio is focused on advancing the manufacturing processes of engineered T-cell receptor (TCR) therapies aimed at treating solid tumors, an area that has historically posed challenges due to the immunosuppressive nature of the tumor microenvironment. The collaboration is geared toward pinpointing critical factors necessary for the successful production of TCR therapies, including the interplay between various T cell conditioning matrices and critical product characteristics like phenotype, metabolic profile, and potency.
Progressing from In Vitro to In Vivo Testing
This collaborative effort has already shown remarkable progress, transitioning from in vitro experiments to in vivo testing. An Investigational New Drug (IND) filing is anticipated soon, targeting the treatment of human papillomavirus-positive tumors using a specially conditioned, engineered TCR therapy.
Innovative AVATAR™ Platforms
Xcellbio developed the AVATAR™ platforms specifically for cell and gene therapy R&D. The AVATAR™ Odyssey system caters to small-scale research and process development needs, while the AVATAR™ Foundry system represents a significant leap as it complies with current Good Manufacturing Practices (cGMP) and introduces groundbreaking capabilities to enhance the potency of cell and gene therapies.
Voices from Leadership
J. Kelly Ganjei, President and CEO of AmplifyBio, expressed enthusiasm about the collaboration: “Building upon our experience with the AVATAR™ Odyssey system, which has equipped us with the tools necessary to optimize various T cell conditioning protocols, we look forward to utilizing the AVATAR Foundry system. This will enable us to push our clients’ research endeavors toward automated, clinical-scale manufacturing of cell products. Our goal is to integrate advanced platforms into our development arsenal that enhance the safety, efficacy, and efficiency of advanced therapies. We are particularly excited about the potential of these tools in expediting the commercialization of therapies targeted at solid tumors, which have historically lagged behind those aimed at hematological malignancies.”
Echoing this sentiment, Brian Feth, co-founder and CEO at Xcellbio, noted: “The AVATAR Foundry system empowers AmplifyBio to assist clients in maximizing the potency and tumor-targeting efficacy of their TCR T product offerings. It will significantly speed up manufacturing timelines while simplifying workflows. We eagerly anticipate collaborating with their team to leverage this powerful technology for the advancement of cell therapy manufacturing, ultimately benefiting future patients.”
Learn More About AVATAR Foundry
The AVATAR Foundry system opens new doors for efficient beta access. For further details on this transformative platform, visit the official Xcellbio website.
About Xcell Biosciences
Xcellbiosciences is committed to enhancing the performance and safety of cell and gene therapies through innovative technology platforms. Their commercial instruments and software empower researchers to extract new insights into immune and tumor biology, ultimately facilitating the advancement of their pioneering cGMP cell therapy manufacturing platform.
About AmplifyBio
AmplifyBio stands as a contract research and manufacturing organization built on the belief that the development and scale-up of advanced modality drugs must align with both commercial and clinical goals from the outset. With a robust initial offering that includes industry-leading preclinical toxicology, safety, and efficacy testing, AmplifyBio has broadened its service to include drug characterization and optimization while establishing a GMP manufacturing facility to support complete concept-to-commercial partnerships for advanced therapy commercialization.
Frequently Asked Questions
What is the purpose of the AVATAR™ Foundry system?
The AVATAR™ Foundry system is designed to enhance the manufacturing capabilities for cell and gene therapy by providing advanced automation suitable for clinical workflows.
How does the partnership between Xcellbiosciences and AmplifyBio benefit cell therapy?
The partnership focuses on optimizing manufacturing processes for T-cell receptor therapies, ultimately leading to improved treatment options for solid tumors.
What advancements have been made in TCR therapy production?
Significant progress has been made from in vitro studies to in vivo testing, with plans for an IND filing aimed at specific tumor types.
Why is the collaboration significant?
This collaboration signifies a major step forward in the fight against solid tumors, improving manufacturing efficiency and targeting capabilities.
What is the mission of Xcell Biosciences?
Xcell Biosciences aims to improve the safety and efficacy of cell and gene therapies through innovative technologies and advanced manufacturing solutions.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.